| Active substance | pegcetacoplan |
| Holder | Swidish Orphan Biovitrum AB |
| Status | closed |
| Indication | Treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who are anaemic despite treatment with a C5 inhibitor for at least 3 months. |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update |
31/03/2023 |